Omeros Corporation (LON: 0KBU)

London flag London · Delayed Price · Currency is GBP · Price in USD
9.35
+0.16 (1.77%)
At close: Jan 21, 2025
142.20%
Market Cap 437.12M
Revenue (ttm) n/a
Net Income (ttm) -100.37M
Shares Out n/a
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 292
Average Volume 3,223
Open 9.44
Previous Close 9.19
Day's Range 9.22 - 9.64
52-Week Range 2.09 - 10.85
Beta n/a
RSI 46.68
Earnings Date Feb 28, 2025

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1994
Employees 198
Stock Exchange London Stock Exchange
Ticker Symbol 0KBU
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.